Bayer's Billion-Euro Balancing Act: Legal Liabilities Cloud Operational Stability

Bayer forecasts a €5B negative cash flow for 2026 due to Monsanto litigation, but maintains its sales and profit guidance. The company's fate hinges on a key US Supreme Court case in April.

Bayer's management insists the company is on track, but a staggering cash outflow tells a different story. For the 2026 fiscal year, the German conglomerate anticipates a massively negative free cash flow of approximately five billion euros. This financial hemorrhage is almost entirely attributable to the enduring legal fallout from the 2018 Monsanto acquisition, with payouts for litigation settlements alone expected to reach up to 2.5 billion euros this year. Since the takeover, Bayer has already spent over $11 billion on settlements and judgments related to its glyphosate-based herbicides.

Despite this drain, the operational business shows resilience. The company has reaffirmed its full-year guidance, targeting currency-adjusted sales of 45 to 47 billion euros and an adjusted EBITDA of 9.6 to 10.1 billion euros. This outlook remains intact even with the imposition of new US tariffs on imported pharmaceuticals, which are capped at 15 percent under a trade agreement, providing some planning certainty. Investors responded with relief to the stable forecast, sending shares up 3.62 percent to 40.69 euros, extending the stock's year-to-date gain to over seven percent.

The immediate future hinges on a series of critical April events. The month culminates in a pivotal legal showdown that could reshape Bayer's financial trajectory for years. On April 27, the US Supreme Court will hear oral arguments in a Missouri case concerning the weedkiller Roundup. The case centers on a $1.25 million award to a man who developed non-Hodgkin lymphoma, with Bayer arguing that federal law preempts state-level warning label requirements. A favorable ruling from the court, expected by the end of its term in June, could invalidate a significant portion of the remaining litigation.

Parallel to the Supreme Court strategy, Bayer is pursuing a second line of defense. A Missouri judge has granted preliminary approval to a $7.25 billion Roundup settlement designed to cover existing and future claims from individuals alleging illness from glyphosate exposure. Claimants have until June 4, 2026, to opt out of this agreement.

Earlier in the month, on April 24, Bayer will hold its virtual Annual General Meeting. Shareholders will vote on a proposed dividend of 0.11 euros per share for the 2025 fiscal year and the election of Marcel Smits and Alfred Stern to the Supervisory Board. The deadline for shareholders to submit countermotions passed at midnight prior to the meeting.

Internally, the company is navigating a crucial pharmaceutical transition. The loss of US patent protection for the blockbuster drug Xarelto is estimated to cost up to 1.5 billion euros in revenue in 2025. To bridge this gap, Pharma chief Stefan Oelrich is pinning hopes on newer drugs Nubeqa and Kerendia. Kerendia received a significant boost in March with EU approval for a new heart failure indication. Management describes 2026 as the final painful transition year before a hoped-for growth phase beginning in 2027, contingent on these new products gaining traction.

CEO Bill Anderson has called the Supreme Court's decision to hear the case an "important step in our multi-faceted strategy to substantially contain this litigation." The outcome will determine whether Bayer can finally stem the cash bleed and secure the financial flexibility needed to fund its promised pharmaceutical growth from 2027 onward.